|
|
 |
|
Viewing report
|
|
|
|
Research Report on Chinese Chemical Pharmaceutical Industry 2010-2011
China Research & Intelligence, Oct 2010, Pages: 70
In China, the chemical pharmaceutical industry includes the chemical API industry and the chemical preparation industry.
The chemical active pharmaceutical ingredients (API) manufacture refers to the production of APIs demanded in the further processing of preparations. It mainly includes the production of chemical substances such as antibiotics, incretions, essential vitamins, etc. The chemical preparation manufacture refers to the production of chemical drug preparations that are directly used for the prevention, treatment and diagnosis of human diseases. These preparations include tablets, injections, capsules, etc. As a sub-industry of the medicine industry, the chemical pharmaceutical industry is attributed to the sector of necessary consumer goods. Therefore, it is not sensitive to the cyclic fluctuation of the macro economy and the international economic environment.
Chinese chemical pharmaceutical industry has its strong points and weak points. On one hand, the chemical API industry shows great advantages in the production scale, market share, techniques and technologies. On the other hand, Chinese chemical preparation industry has low development level and less competitiveness. In China, over 95% homemade medicines are generic ones. The patent drug and expired patent drug (brand-name drug) market is almost totally occupied by foreign-funded or joint venture medicine enterprises. The technological level of Chinese local pharmaceutical enterprises generally lags behind that of transnational pharmaceutical enterprises. Chinese local pharmaceutical enterprises produce medicines mainly by imitation, which is complemented with some innovation. China is now a large export country of chemical APIs.
In 2009, the total sales in Chinese chemical pharmaceutical industry reached CNY 424.24 billion, rising by 18.24% YOY. In 2009, China’s total import and export value of chemical medicines amounted to USD 32.79 billion, rising by 8.03% YOY. The export value was USD 19.20 billion, dropping by 0.8% YOY; the import value was USD 13.59 billion, rising by 23.59% YOY.
In the heavily-populated China, the medicine consumption capacity will be improved with the increase of residents’ income and the intensification of their healthcare awareness. Moreover, the volume of the elderly in China is rising, and they are one of the largest consumer groups of medicines. With the constant reform and perfection of China’s medical system and the enhancement of the universality and fairness of the social security system, the seriously suppressed demand in the medicine market will gradually be released.
Through this report, readers can acquire more information:
- Status quo of Chinese chemical pharmaceutical industry
- Competition in Chinese chemical pharmaceutical industry
- Status quo of Chinese API industry
- Development of Chinese chemical pharmaceutical industry by region
- Operation of major enterprises in Chinese chemical pharmaceutical industry
- Import and export of Chinese chemical pharmaceutical industry
- Prediction on development of Chinese chemical pharmaceutical industry
- Prediction on investment of Chinese chemical pharmaceutical industry
Following persons are recommended to buy this report:
- Medicine producers
- Medicine traders
- Medicine R&D institutes
- Investors concerning Chinese medicine industry
- Research institutes concerning Chinese medicine industry
- Correlative enterprises along the medicine industry chain
Customers who bought this item also bought
China's Heparin Industry Report, 2010-2011
China Chemical Pharmaceutical Industry Report, 2009-2010
China Chemical Pharmaceutical Industry Report, 2009-2010
The New Trend of API Sourcing and Contract Manufacturing in China
China Chemical Pharmaceutical Industry Report, 2011
China Chemical Pharmaceutical Industry Report, 2011
Research Report on Top 50 Companies of China's Pharmaceutical Industry, 2011-2012
China's Heparin Industry Report, 2010-2011
Market of Paclitaxel Injection in China
Research Report on Chinese Avermectin Industry, 2009-2010
|
|
|
|
